跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PCSK9 targeting
首页
药物
PCSK9 targeting
PCSK9 targeting
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER
EP 3340994 A1
申请人: ALNYLAM PHARMACEUTICALS INC
优先权: 2015
CN
EP
US
WO
15 件公开
PCSK9 IRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP 2929031 A1
申请人: ALNYLAM PHARMACEUTICALS INC
优先权: 2012
CN
EP
US
WO
10 件公开
COMPOSITIONS AND METHODS FOR THE TARGETING OF PCSK9
EP 4314267 A1
申请人: SCRIBE THERAPEUTICS INC
优先权: 2022
CN
EP
US
WO
7 件公开
EP 4087930 A1
申请人: SCRIBE THERAPEUTICS INC
优先权: 2020
CN
EP
US
WO
4 件公开
EP 4536819 A1
申请人: SCRIBE THERAPEUTICS INC
优先权: 2022
EP
US
WO
3 件公开
EP 4689082 A1
申请人: SCRIBE THERAPEUTICS INC
优先权: 2023
EP
WO
2 件公开
ANTISENSE OLIGOMERS AND CONJUGATES TARGETING PCSK9
EP 3591054 A1
申请人: ROCHE INNOVATION CT COPENHAGEN AS
优先权: 2013
EP
US
7 件公开
Targeting rare human PCSK9 variants for cholesterol treatment
US 8883157 B1
申请人: KYMAB LTD
优先权: 2013
US
7 件公开
US 9023359 B1
申请人: KYMAB LTD
优先权: 2014
US
4 件公开
US 9051378 B1
申请人: KYMAB LTD
优先权: 2014
US
ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9
EP 4259799 A4
申请人: CIVI BIOPHARMA INC
优先权: 2020
EP
US
WO
6 件公开
SIRNAS FOR SIMULTANEOUSLY INHIBITING EXPRESSION OF TWO TARGET GENES, DRUG AND USE THEREOF
US 20260226469 A1
申请人: BEBETTER MED INC
优先权: 2023
CN
EP
US
WO
5 件公开
Lipid formulated dsRNA targeting the PCSK9 gene
US 8273869 B2
申请人: FITZGERALD KEVIN
优先权: 2010
US
5 件公开
COMPOSITIONS AND METHODS FOR INHIBITING PCSK9
US 2022290156 A1
申请人: SANOFI SA
优先权: 2019
CN
EP
US
WO
4 件公开
POLYNUCLEIC ACID MOLECULES TARGETING PCSK9 AND USES THEREOF
EP 4405483 A4
申请人: SIRIUS THERAPEUTICS INC
优先权: 2021
CN
EP
US
WO
4 件公开
第 1 / 6 页
上一页
下一页
药物
反馈